Investigation Of Cyp2c9 Gene Polymorphism In Patients Receiving Warfarin Therapy

Abstract

Purpose: The aim of the study is to investigate the relationship between CYP2C9 gene polymorphism status and weekly dose requirement and INR levels in patients who are receiving Varfarin treatment and admitted to our hospital. Materials and methods: A total of 100 patients and 100 control groups who applied to the Emergency Department of Pamukkale University Medical Faculty, who used Warfarin treatment were included in the study. Results: CYP2C9*1 allele frequency 74%, CYP2C9*2 allele frequency 8.5%, CYP2C9*3 allele frequency 17.5%, CYP2C9*1/*1 genotype frequency %54, CYP2C9*1/*2 genotype frequency 11%, CYP2C9*1/*3 genotype frequency 29%, CYP2C9*2/*3 genotype frequency 6% were found in the group using Varfarin. When the Warfarin group was measured according to CYP2C9 genotypes and alleles, there was no statistically significant difference between the genotypes or alleles in terms of INR levels (p=0.475 and p=0.483, respectively). In the INR measurements performed in the first control after the use of Warfarin, the INR level was found to be significantly lower in individuals with wild type genotype or allele compared to individuals with other genotypes and alleles (p=0.038 and p=0.032, respectively). The peak INR value measured during Warfarin treatment was likewise lower in wild-type individuals than in individuals with other genotypes or alleles (p=0.0001 and p=0.008, respectively). Conclusion: The fact that the first and peak INR values of patients carrying the mutant allele or genotypes of the CYP2C9 gene were higher than the non-mutated group reveals the effect of these alleles on Warfarin metabolism. © 2020, Pamukkale University. All rights reserved.